If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-23. Numbers and descriptions here follow the published literature rather than marketing material.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
== Medical uses == Antithrombin is used as a protein therapeutic that can be purified from human plasma or produced recombinantly (for example Atryn, which is produced in the milk of genetically modified goats). It is approved by the FDA as an anticoagulant for the prevention of clots before, during, or after surgery or birthing in patients with hereditary antithrombin deficiency. It has been studied in sepsis to reduce diffuse intravascular coagulation and other outcomes. It has not been found to confer any benefit in critically ill people with sepsis.
=== Art === The Cherokee Heritage Center is home to the Cherokee National Museum, which has numerous exhibitions also open to the public. The CHC is the repository for the Cherokee Nation as its National Archives. The CHC operates under the Cherokee National Historical Society, Inc., and is governed by a board of trustees with an executive committee. The nation also supports the Cherokee Nation Film Festivals in Tahlequah and participates in the Sundance Film Festival in Park City, Utah.
The Phoenicians also made a deep blue-coloured dye, sometimes referred to as royal blue or hyacinth purple, which was made from a closely related species of marine snail. The Phoenicians established an ancillary production facility on the Iles Purpuraires at Mogador, in Morocco. The sea snail harvested at this western Moroccan dye production facility was Hexaplex trunculus, also known by the older name Murex trunculus. This second species of dye murex is found today on the Mediterranean and Atlantic coasts of Europe and Africa (Spain, Portugal, Morocco).
Original (black can with green logo) Zero Sugar (originally had dark blue logo; changed to resemble Original can with the top recolored green with a black pull tab) Lo-Carb (black can with dark blue logo) Assault (cola flavor, stylized camouflage can with red logo) Reserve White Pineapple (pineapple flavor, black can with yellow logo and yellow band around flavor title) Reserve Orange Dreamsicle (orange flavor, black can with orange logo) Reserve Watermelon (watermelon flavor, black can with red logo) Ripper (tropical fruits flavor, yellow can) Cuba-Libre (cola and lime flavor version of the cuba libre cocktail.) Dub Mad Dog (grape flavor, discontinued) Maxx (original flavor with added nitrous oxide, comes in a variety of flavors) Nitro Super Dry (citrus flavor; utilizes nitrous oxide rather than carbon dioxide, giving the beverage a light & dry texture (mouthfeel) similar to that of fine champagne, black can with black logo shrouded in lime green) Mule (ginger beer flavor, zero sugar, matte finish black can with bronze logo and text with 'Non-alcoholic', inspired to the Moscow Mule cocktail) VR46 The Doctor (orange flavor, yellow can with Valentino Rossi's The Doctor branding) LH44 Lewis Hamilton (red can with yellow and black patterns with black logo) Full Throttle (previously named Lewis Hamilton too, blue can with white text and yellow logo) Java (Coffee mixed with Monster Energy available in a variety of flavors including salted caramel, loca moca, Irish cream, and mean bean.) Pacific Punch (cherry punch flavor) Pipeline Punch (passion fruit, orange and guava flavor, pink can) Mixxd (Punch line. Cherry flavor, surface-textured purple can.) Monarch (juiced line, pastel pink can with yellow logo and Monarch butterfly artwork) Mango Loco (juiced line, blue can with orange logo and artwork themed to the Mexican Day of the Dead) Khaotic (juiced line, yellow can with light blue logo and graffiti butterfly artwork) Aussie Lemonade style (Juiced line, blue can with yellow logo and artwork featuring a variety of sea creatures. Citrus flavored. Introduced in 2022) Bad Apple (juiced line, red apple flavor, punky/alt version of Eve holding an apple) Rio Punch™ (juice line, sweet papaya, vanilla ice cream, hint of blackcurrant, green can with yellow diamond themed to the Brazilian flag.) Viking Berry™ (juice line, mixed nordic berries, blackberry, black currant, hint of lingonberry, sweet and tart profile, red and light blue can with norse themed art.) Voodoo Grape™ (juice line, Concord, Niagara, and red grape profile, yellow and purple can with Louisiana voodoo-themed artwork) Zero Ultra (citrus flavor, zero sugar, textured white can with silver logo) Commonly known as "White Monster" Lando Norris Zero Sugar (melon yuzu flavour, black can with neon yellow pattern) Ultra Blue (blue raspberry flavor with a light citrus and berry flavor profile, zero sugar, textured light blue can with silver logo) Ultra Fantasy Ruby Red (grapefruit flavor, zero sugar, textured magenta can with silver logo) Ultra Fiesta (mango flavor, zero sugar, textured blue can with silver logo) Ultra Watermelon (watermelon flavor, zero sugar, textured bright red can with silver logo) Ultra Paradise (apple and kiwi flavor, zero sugar, textured lime green can with silver logo) Ultra Rosá (pink lemonade flavor, zero sugar, textured hot pink can with silver logo) Ultra Gold (pineapple flavor, zero sugar, textured gold can with silver logo) Ultra Vice Guava (guava flavor, zero sugar, textured teal can with pink-white logo) Ultra Red (mixed berry flavor, zero sugar, red can) Ultra Black (cherry flavor, zero sugar, textured black can with silver logo) Ultra Peachy Keen (Peach flavor, zero sugar, textured peach can with silver logo. Made in limited edition form.) Ultra Sunrise (Orange flavor, zero sugar, orange can with silver logo) Ultra Strawberry Dreams (strawberry flavor, zero sugar, pink can) Ultra Passion (passionfruit flavour) Ultra Red, White, and Blue (rocket pop flavour) Ultra Violet, a.k.a. The Purple Monster (grape flavor, zero sugar, violet can)
Sources: en.wikipedia.org
Namandjé N. Bumpus is an American pharmacologist who served as the Principal Deputy Commissioner of the Food and Drug Administration. She was previously director of the department of pharmacology and molecular sciences at Johns Hopkins University School of Medicine, where she held the E.K. Marshall and Thomas H. Maren professorship in pharmacology.
An inhibitor cystine knot (also known as ICK or Knottin) is a protein structural motif containing three disulfide bridges. Knottins are one of three folds in the cystine knot motif; the other closely related knots are the growth factor cystine knot (GFCK) and the cyclic cystine knot (CCK; cyclotide). Types include a) cyclic mobius, b) cyclic bracelet and c) acyclic inhibitor knottins. Cystine knot motifs are found frequently in nature in a plethora of plants, animals, and fungi and serve diverse functions from appetite suppression to anti-fungal activity. Along with the sections of polypeptide between them, two disulfides form a loop through which the third disulfide bond (linking the third and sixth cysteines in the sequence) passes, forming a knot. The motif is common in invertebrate toxins such as those from arachnids and molluscs. The motif is also found in some inhibitor proteins found in plants, but the plant and animal motifs are thought to be a product of convergent evolution. The ICK motif is a very stable protein structure which is resistant to heat denaturation and proteolysis. CK peptide components of venoms target voltage-gated ion channels but members of the family also act as antibacterial and haemolytic agents. Plant ICK proteins are often protease inhibitors. Knottins have high stability to pH, heat, and enzymes. Because of their stability and their favorable pharmacodynamic properties, knottins are becoming increasingly popular as protein engineering scaffolds.
Many Sudeten Germans also opposed joining Austria, arguing that being incorporated into Austria would turn Sudeten lands into "economically helpless Austrian enclaves". Because of this, Sudetenland becoming part of Czechoslovakia was the preferable choice of "a good deal of cautious middle-class" amongst Sudeten Germans. Silesian-Sudeten Germans were particularly pro-Czechoslovak, as they strongly preferred Czechoslovak rule to the prospect of becoming a part of Poland.
Sources: en.wikipedia.org
=== Breastfeeding === Mothers utilizing recreational drugs, such as cocaine, methamphetamines, PCP, and heroin, should not breastfeed. The March of Dimes said "it is likely that cocaine will reach the baby through breast milk," and advises the following regarding cocaine use during pregnancy:
== Applications == Many derivatives of early metal metallocenes are active catalysts for olefin polymerization. Unlike traditional and still dominant heterogeneous Ziegler–Natta catalysts, metallocene catalysts are homogeneous. Early metal metallocene derivatives, e.g. Tebbe's reagent, Petasis reagent, and Schwartz's reagent are useful in specialized organic synthetic operations.
=== Pregnancy === Lamividine/zidovudine is categorized pregnancy category C in the United States, meaning there are potential risks to the baby during pregnancy, but potential benefits may outweigh the risks. Data supports the safety of this combination during pregnancy and is often preferred over other fixed dose combinations during pregnancy.
Suvorexant appeared to be similarly effective at 4 weeks to lemborexant (SMD 0.36, 95% CI 0.08 to 0.63) and daridorexant (SMD 0.23, 95% CI –0.01 to 0.48), whereas benzodiazepines and Z-drugs generally showed larger effect sizes (e.g., SMDs of 0.45 to 0.83) and antihistamines (e.g., doxepin, doxylamine, trimipramine) showed more similar efficacy (SMDs of 0.30 to 0.55). Orexin receptor antagonists like suvorexant increase total sleep time predominantly by increasing rapid eye movement sleep (REM) sleep, whereas they have no effect on or even decrease non-rapid eye movement (NREM) sleep. This is in contrast to most other hypnotics, which either do not affect REM sleep or decrease it. The implications of these differences are not fully clear. Unlike certain other hypnotics like benzodiazepines and Z-drugs, orexin receptor antagonists do not disrupt sleep architecture, and this might provide more restful sleep. It is unclear if suvorexant is safe among people with a history of substance addiction or alcoholism, as these individuals were excluded from clinical trials of suvorexant. A Cochrane review found suvorexant to be effective in the short-term treatment of sleep disturbances in people with dementia with few adverse effects. It is unknown if suvorexant is effective and safe for treatment of sleep problems in children and adolescents as suvorexant has not been studied in this context.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.